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Interlukien-1 b (IL-1b)Abstract Background: Oral mucositis is the most common side effects of chemotherapy of all can-
cer with intensive treatments regimen, and is the most common side effects of head and neck radi-
ation therapy. For steam cell transplantation, its also regarded as the most debilitating side effects.
Aims of the study: The objectives of this study were to assess the effect of a mouth rinse contain-
ing olive leaf extract (OLE) in preventing severe oral mucositis in patients receiving chemotherapy,
and to estimate its effect in decreasing pro-inﬂammatory cytokine production after chemotherapy.
Materials and methods: This study utilized a placebo-controlled, randomized, double-blind, and
cross-over design. Twenty-ﬁve patients undergoing intensive chemotherapy were randomly assigned
to receive a mouth wash containing OLE, benzydamine hydrochloride, or placebo in 3 different
cycles of chemotherapy. Oral mucositis severity was assessed using the World Health Organization
criteria and Oral Mycositis Assessment Scale. Patients were evaluated weekly until 15 days after
chemotherapy for each cycle. Salivary levels of interleukin-1 beta (IL-1b) and tumor necrosis fac-
tor-alpha (TNF-a) were evaluated by enzyme-linked immunosorbant assay.
Results: Oral mucositis rates and severity after 2 weeks were signiﬁcantly lower in the OLE and
benzydamine groups compared to the placebo group. The IL-1b and TNF-a levels were signiﬁ-
cantly decreased in the OLE group compared to the other groups.
Conclusion: Preliminary ﬁndings indicate that OLE is effective in reducing IL-1b andTNF-a levels
after chemotherapy and exert a therapeutic effect and prevent development of severe oral mucositis.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Oral mucositis is a common, debilitating, and painful side ef-
fect of chemo- and radio-therapies of head and neck malignan-
cies (Elad et al., 2011). By virtue of their rapid mitotic rate,
142 K.M. Ahmedmucosal cells in the lining of gastrointestinal tract are natural
targets of cancer cytotoxic regimens (Raber-Durlacher et al.,
2010). At the clinical level, oral mucositis typically manifests
as atrophy, swelling, erythema, and ulceration. The condition
may be exacerbated by local factors, such as trauma from
teeth, or microbial colonization (Raber-Durlacher et al.,
2010). Oral mucositis has a signiﬁcant impact on the patient’s
quality of life. Severe oral mucositis is one of the leading causes
of unplanned treatment interruption, chemotherapeutic dose
reductions, and changes in the selection of anti-neoplastic
agents (Chen et al., 2011).
Recently, a biological model for chemotherapy- and radio-
therapy-induced oral mucositis was proposed by Sonis et al.
(2004), which revealed the complexity of the pathogenesis of
this disease. The model described mucositis events in 5 over-
lapping phases: initiation, signaling with messenger generation,
ampliﬁcation, ulceration, and healing, with pro-inﬂammatory
cytokines playing an important role. Cytokine release can lead
to tissue injury, apoptosis, and loss of epithelial integrity, with
consequent ulcer development. Due to the complex patholog-
ical process of oral mucositis, no intervention is available to
prevent or treat the condition on its own. Many interventions
can be found in the literature, including some that may be
highly protective in one set of circumstances, but have little
or no effect or may even be detrimental in others (Duncan
and Grant, 2003). Researchers have suggested the need to
combine interventions that act on different phases of mucositis
(Rodriguez-Caballero et al., 2012).
Palifermin is among the recent target therapies formucositis.
This drug alters the cytokine proﬁles, speciﬁcally down-regulat-
ing tumor necrosis factor (TNF) (Potting et al., 2006; Logan
et al., 2007). This ﬁnding has provided further support for the
role of cytokines in the development of mucosal toxicity (Spiel-
berger et al., 2004; Potting et al., 2006). Benzydamine hydrochlo-
ride, an oral rinse with analgesic, anesthetic, anti-inﬂammatory,
and antimicrobial activities (Sonis, 2004; Silverman, 2007), has
been shown to decrease the risk of oral mucositis development
in several clinical settings (Kim et al., 1986; Prada and Chiesa,
1987; Epstein et al., 1989). It also appears to reduce erythema
and ulceration after radiotherapy (Epstein et al., 2001) and che-
motherapy (Cheng, 2004; Cheng et al., 2004).
Olive leaf extract (OLE) is a natural product that has been
used as a medicament since ancient times. Throughout history,
the olive plant has been an important source of nutrition and
medicine. The therapeutic use of the olive plant has even been
mentioned in Holy books. OLE exerts antioxidant (Visioli and
Galli, 2002), anti-inﬂammatory (de la Puerta et al., 2000), and
antimicrobial activities against bacteria (Walker, 1996), viruses
(Lee-Huang et al., 2007), fungi, and mycoplasma (Aziz et al.,
1998; Markin et al., 2003). Traditionally, OLE has been used
to treat and prevent hypertension through its hypoglycemic,
antiseptic, and diuretic properties (Coni et al., 2000; Manna
et al., 2004; Andreadou et al., 2007; Singh et al., 2008). Recent
studies have demonstrated the anticancer effects of OLE
(Hamdi and Castellon, 2005; Abaza et al., 2007). For example,
Atai et al. (2007) compared topical OLE with topical dexa-
methasone elixir for the treatment of recurrent aphthus ulcer-
ation, ﬁnding that both medications similarly reduced ulcer
size and decreased pain. Only one study has examined the ef-
fect of OLE in reducing cancer-related complications; a doc-
toral dissertation study by Talabani et al. (2010) evaluated
the effect of OLE in preventing and treating oral mucositis.To our knowledge, no study in the literature has evaluated
the effect of OLE on pro-inﬂammatory cytokine expression in
cancer patients receiving chemotherapy. Accordingly, the pur-
pose of this study was to investigate the ability of OLE to pre-
vent or delay the appearance of severe oral mucositis in cancer
patients receiving chemotherapy. Its effect was compared with
that of benzydamine hydrochloride as a positive control and
placebo as a negative control. Cytological assays were used
to examine the effects of the drugs on the proﬁles of two
pro-inﬂammatory cytokines: interleukin-1 beta (IL-1b) and
TNF alpha (TNF-a).
2. Patients, materials, and methods
2.1. Setting and patients
The study was carried out at the Hiwa Oncology Hospital in
Sulaimani City (Kurdistan region/Iraq) between December
2011 and June 2012. Twenty-ﬁve consecutive cancer patients
(children and adults) who were under intensive cancer treat-
ment participated in this study. All procedures were conducted
in accordance with the guidelines approved by the local ethics
committee of the University of Sulaimani. Fig. 1 shows a sche-
matic for the design of the study.
The inclusion criteria of this study were as follows: (1) pa-
tients receiving intensive cancer treatment (high dose of a sin-
gle cytotoxic drug or combinations of multiple cytotoxic
drugs); (2) absence of prophylactic local treatment for mucosi-
tis; and (3) informed consent provided by the patient or their
parents/guardians. A patient was excluded from participation
in the study if any of the following exclusion criteria applied:
(1) patients under non-intensive chemotherapeutic treatment;
(2) patients taking prophylactic local medication for oral
mucositis; and (3) patients who requested to leave or be ex-
cluded from the study.
2.2. Study design
A prospective, randomized, double-blind, placebo-controlled,
cross-over study design was selected. There were a few reasons
for the choice of study design. First, it was extremely difﬁcult
to control for all therapy- and patient-speciﬁc variables in a
single-center study. Second, from a practical perspective, it
was difﬁcult to obtain sufﬁcient numbers of participants in
the study time period who met all of the inclusion criteria.
2.3. Oral treatment regimen
Mouth rinse solutions
 OLE (333 mg/ml Olea europaea L., St. Francis Herb Farm
Inc. Combermere, Canada)
 Benzydamine hydrochloride (0.15 g/100 ml, EPICO, Egypt;
under License of F.ANGELINI ITALY).
 Normal saline, as placebo.
Eligible patients were randomized to receive benzydamine
hydrochloride, OLE, or placebo in the form of a mouth rinse.
This oral treatment was changed in the next chemotherapy cy-
cle for each patient (cross-over design). The studied drugs were
self-administered 3–4 times daily for 14 days, starting on the
Followed up (evaluating oral 
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mucositis, on days 1, 8 and 15) 
(No=31)
Followed up (evaluating oral 
mucositis, on days 1, 8 and 15) 
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travel outside country for further 
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25 patients completed the trial 
Statistical analysis, Descriptive and analytical 
statistic (T test, ANOVA, and Man Whitney U 
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Hospital and local ethical committee in University of Sulaimani
Figure 1 Showing design of the trial.
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mouth with water before applying the oral treatment, to re-
move any remnants of food particles. They were also asked
to maintain good oral hygiene by brushing with a soft bristle
brush daily.
2.4. Scoring and monitoring oral mucositis
During the study period, the tested oral treatments were visu-
ally evaluated on days 1, 8, and 15 of each cycle of chemother-
apy. On these days, a follow-up case sheet was ﬁlled out for
each patient.
Oral mucositis was scored according to the Oral Mucositis
Assessment Scale (OMAS) and the World Health Organiza-
tion (WHO) score as described by WHO (1979) and Sonis
et al. (1999). Oral mucositis was measured before the mouth
wash was used on days 1, 8, and 15. The two scoring systems
were applied to be able to compare outcomes with ﬁndings
from the literature that used either scoring system. The OMAS
measures 9 sites in the mouth for erythema, pseudomem-
branes, or ulcerations. The mean score of OMAS ranges from 0
to 5. The WHO score is as follows: grade 0 = normal,
no mucositis; grade 1 = soreness and erythema; grade2 = erythema, ulceration, can eat solids; grade 3 = ulcers re-
quire liquid diet only; and grade 4 = alimentation not
possible.
2.5. Collection of saliva samples
Saliva samples were collected from each patient before starting
the oral treatment (on day 1) and at the end of oral treatment
(on day 15). Whole unstimulated saliva (WUS) was collected
between 9:00 and 11:00 AM by the method described by Zhang
et al. (2008). Patients were asked to refrain from eating and
drinking for at least 30 min before sampling. All patients were
requested to swallow ﬁrst, tilt their head foreword, and then
expectorate all saliva into a sterile container without swallow-
ing for 5 min.
Samples were immediately transported to a laboratory and
centrifuged for 20 min at 4000 rpm. If a cell pellet was not vis-
ible, then the sample was recentrifuged. The cleared saliva
supernatant was decanted into a 1.0 ml sterile Eppendorf tube.
All saliva samples were immediately frozen at 80 C for fur-
ther usage.
Following the manufacturer’s instructions (Biotech, USA),
assays for IL-1b and TNF-a were performed.
Table 2 The mean OMAS mucositis score for the tested drugs
at different times.
Tested drugs OMAS at diﬀerent times (days)
Mean ± SD
1 8 15
P< 0.05 P< 0.001 P< 0.001
Benzydamine HCl 0.04 ± 0.12 0.43 ± 0.42 0.18 ± 0.22
Olive leaf extract 0.06 ± 0.14 0.11 ± 0.15 0.02 ± 0.04
*P value statistically highly signiﬁcant between OMAS and tested
drugs, Benzydamine HCl: Benzydamine Hydrochloride.
Table 3 Mean OMAS mucositis score for the tested drugs
using post hoc test.
Drugs Times (days)
Mean OMAS± SD
1 8 15
P< 0.05 P< 0.001 P< 0.001
Benzydamine HCl 0.04 ± 0.122 0.43 ± 0.429 0.18 ± 0.227
Placebo 0.16 ± 0.218 1.06 ± 0.293 0.60 ± 0.246
P> 0.05 P< 0.01 P< 0.01
Benzydamine HCl 0.04 ± 0.12 0.43 ± 0.42 0.18 ± 0.22
Olive leaf extract 0.06 ± 0.14 0.11 ± 0.15 0.02 ± 0.04
P> 0.05 P< 0.001 P< 0.001
Olive leaf extract 0.06 ± 0.14 0.11 ± 0.15 0.02 ± 0.04
Placebo 0.16 ± 0.21 1.06 ± 0.29 0.60 ± 0.24
*P value statistically highly signiﬁcant between OMAS and tested
drugs.
Table 4 The WHO grades for the tested drugs at different times.
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For all samples, data were collected in a case sheet, entered
into the EXCEL software program, and analyzed using the
Statistical Package for Social Sciences (SPSS) version 13 soft-
ware package. Simple descriptive analysis was used for some
variables (gender, age, and tumor type). Different statistical
tests, such as analysis of variance (ANOVA), Spearman rank
correlation coefﬁcients, and Fisher’s exact, Mann–Whitney,
and chi-square tests, were used to ﬁnd associations between
different variables. A P-value <0.05 was regarded as statisti-
cally signiﬁcant.
3. Results
3.1. Demographic and baseline characteristics
Table 1 lists the demographic data and tumor types for all patients.
Most patients had leukemia (Acute Myeloid Leukemia (AML), Acute
Lymphoblastic Leukemia (ALL)). The mean age of participants was
32 years, the age range was (10–40).
3.2. Oral mucositis assessment
The mean OMAS results on different days are shown in Tables 2 and
3. The lowest mean values were recorded in the OLE group, followed
by the benzydamine and placebo groups, respectively. Changes in the
OMAS results were statistically highly signiﬁcant (P value 6 0.01). The
mean OMAS values were low on day 1 (ﬁrst day after receiving chemo-
therapy). On days 8 and 15, the mean OMAS values were increased
signiﬁcantly in the placebo group compared to the OLE and benzyd-
amine groups. Oral mucositis grades according to WHO grading sys-
tem are shown in Table 4. The OLE group showed no grade 3 or 4
results. Grades 2, 3, and 4 were more common in the placebo group
compared to the benzydamine group.
3.3. Level of pro-inﬂammatory cytokines in WUS
The IL-1b and TNF-a levels in the WUS of patients receiving chemo-
therapy were signiﬁcantly decreased after applying OLE for 2 weeks.
Levels of both cytokines, especially IL-1b, were signiﬁcantly increasedTable 1 Patient characterization, type of tumor and drug
groups.
Variables Frequency (%)
Sex
Male 13(52%)
Female 12(48%)
Ages
Age range (32.0)
Mean ± SD 20.5 (9.0)
Type tumor
AML 7(28%)
ALL 7(28%)
Burkitt Lymphoma 6(24%)
HL 2(8%)
NHL 2(8%)
Multiple myeloma 1(4%)
AML: acute myeloid leukemia, ALL: acute lymphoblastic leuke-
mia, HL: hodgkin’s lymphoma, NHL: non hodgkin’s lymphoma.
WHO Grading
at diﬀerent times
Tested drugs P value
Benzydamine
HCl
Olive
Leaf
Placebo
N (%) N (%) N (%)
Day 1
Grade 0 22(88.0) 20(80.0) 13(52.0) P< 0.05
Grade 1 2(8.0) 4(16.0) 11(44.0)
Grade 2 1(4.0) 1(4.0) 1(4.0)
Days 8
Grade 0 8(32.0) 15(60.0) 0(0.0) P< 0.001
Grade 1 7(28.0) 8(32.0) 1(4.0)
Grade 2 7(28.0) 2(8.0) 6(24.0)
Grade 3 3(12.0) 0(0.0) 0(0.0) 15(60.0)
Grade 4 0(0.0) 15(60.0) 3(12.0)
Days 15
Grade 0 13(52.0) 22(88.0) 0(0.0) P< 0.001
Grade 1 9(36.0) 3(12.0) 5(20.0)
Grade 2 3(12.0) 0(0.0) 0(0.0) 15(60.0)
Grade 3 0(0.0) 22(88.0) 5(20.0)
Benzydamine HCl: benzydamine hydrochloride, WHO: world health
organization.
Table 6 The level of IL-1b before and after using the tested
drugs.
Diﬀerent materials Interleukin 1-b P value
Pre treatment Post treatment
Mean ± SD Mean ± SD
Benzydamine HCl 78.3 ± 76.2 66.6 ± 69.3 0.572
Olive leaf extract 117.7 ± 1.6 21.2 ± 53.3 0.001
Placebo 51.4 ± 55.5 112.4 ± 71.0 0.001
The bold font shows the signiﬁcant P value.
Table 5 The level of TNF-a before and after using the tested
drugs.
Diﬀerent materials Tumor necrosis factor-a P value
Pre treatment Post treatment
Mean ± SD Mean ± SD
Benzydamine HCl 48.4 ± 81.7 55.3 ± 1.2 0.817
Olive leaf extract 101.5 ± 64.5 51.9 ± 56.2 0.006
Placebo 76.3 ± 2.4 188.9 ± 3.2 0.172
The bold font shows the signiﬁcant P value.
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of both cytokines were decreased, but there were no signiﬁcant changes
(Tables 5 and 6).
4. Discussion
Despite the current understanding of the complex development
of oral mucositis in cancer patients, no interventions are avail-
able for the prevention or treatment of this disorder. Interven-
tions that target only one aspect of the mucositis
pathobiological process have been reported to be largely inef-
fective (Stokman et al., 2006). Treatments should be directed
toward multiple biological targets of the mucositis process,
either by using an intervention with multiple mechanistic ef-
fects or using a combination of interventions. Palifermin has
largely been accepted as the drug of choice (within certain lim-
itations) for the prevention and treatment of mucositis (Spiel-
berger et al., 2004; Blijlevens and Sonis, 2007; Sonis, 2007,
2009). However, this drug is given through an intravenous
route, not as a topical application. Thus, cancer treatment cen-
ters continue to search for new drugs for oral mucositis pre-
vention and treatment.
To conduct clinical trials of mucositis prevention, it is nec-
essary to have reliable, valid, sensitive, and easy-to-use instru-
ments. Through considerable effort, various mucositis scales
have been developed for cancer patients undergoing chemo-
therapy and radiotherapy. The WHO scale is a functional
and subjective scale for the clinical assessment of patients
receiving cancer therapy, whereas the OMAS is a detailed
objective scoring scale that was designed for clinical research
trials. In the current study, both scales were used for clinical
assessment of oral mucositis severity. The purpose behind
using both scales was to assess the effect of the tested drugs
on the subjective, functional, and objective outcomes of oralmucositis severity. According to Sung et al. (2007), the use
of both instruments should provide a measure of both the
severity and effects of mucositis (i.e., impact on the ability to
eat and drink).
According to the pathobiology of oral mucositis (Sonis
et al., 2004; Sonis, 2007), an increase in pro-inﬂammatory
cytokines is associated with mucositis development and likely
plays important roles in mediating injury and signaling. The
intensity of pro-inﬂammatory cytokine production is increased
before tissue damage and precedes the clinical appearance of
oral mucositis (Yeoh et al., 2005; Sonis, 2007; Logan et al.,
2007; Logan et al., 2009). This fact might explain the high lev-
els of IL-1b and TNF-a in all 3 groups before administration
of the tested treatments on the ﬁrst day after chemotherapy.
After the tested treatments were applied for 2 weeks, the inten-
sities of both cytokines were decreased in the OLE and benzyd-
amine groups, whereas the placebo group showed an increase
in cytokine levels. This ﬁnding might be related to the effect of
the tested treatments, with the placebo revealing lower activity
toward the studied cytokines.
Although clinically the benzydamine and OLE groups
showed lower mean OMAS and less severe WHO results com-
pared to the placebo group, a statistically signiﬁcant reduc-
tion in pro-inﬂammatory cytokine levels was only observed
in the OLE group. A reduction in the expression of these
cytokines is important for several reasons. First, the risk of
oral mucositis remains and increases cumulatively with each
cycle of chemotherapy. Second, the mucositis pathobiology
(Sonis, 2007, 2009) suggests that submucosal damage in the
endothelium will develop even in the absence of clinically vis-
ible lesions in the oral epithelium. In other words, our ﬁnd-
ings indicate that oral rinsing with OLE decreased the risk
of developing severe oral mucositis for the next cycle of
chemotherapy.
In conclusion, this study demonstrates, for what we believe
to be the ﬁrst time, that the use of a mouth wash containing
OLE during chemotherapy can decrease the expression levels
of IL-1b and TNF-a. This result might be due to the fact that
OLE is effective against a wide range of oral microorganisms
(Walker, 1996; Lee-Huang et al., 2007; Aziz et al., 1998; Mar-
kin et al., 2003). By reducing the impact of the oral microbial
ﬂora, OLE can help reduce cancer therapy-related complica-
tions and prevent further activation of pro-inﬂammatory cyto-
kines through a negative feedback mechanism, as elaborated in
the 5-stage model of oral mucositis (Sonis et al., 2004; Sonis,
2007, 2009).
Another explanation might be the antioxidant (Visioli and
Galli, 2002) and anti-inﬂammatory (de la Puerta et al., 2000)
nature of OLE. Benzydamine has also been demonstrated to
exert antioxidant and anti-inﬂammatory effects, by decreasing
the synthesis of IL-1b and TNF-a (Sironi et al., 1997; Ryu
et al., 2007; Niscola et al., 2009). However, in the present
study, benzydamine showed a weaker anti-inﬂammatory effect
against IL-1b and TNF-a compared to OLE at 2 weeks after
chemotherapy. This ﬁnding might suggest that OLE has a
stronger anti-inﬂammatory action compared to benzydamine.
Within the limitations of the study like the number of patients,
the study period, and the randomization by computer block,
these preliminary results indicate that further studies are war-
ranted to investigate the effects of OLE in decreasing cancer-
related complications.
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